ESSA Pharma Inc. (EPIX)

6.82 +0.20 (+3.02%) 市場開市。 截至 02:49PM EDT。

ESSA Pharma Inc.

999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada
778 331 0962
https://www.essapharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 50

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. David Ross Parkinson M.D.	President, CEO & Director	814.15k	無	1950
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA	Chief Financial Officer	590.39k	無	1957
Mr. Peter A. Virsik M.B.A., M.S.	Executive VP & COO	645.95k	無	1971
Dr. Alessandra Cesano M.D., Ph.D.	Chief Medical Officer & Executive VP	623.93k	無	1961
Chandtip Chandhasin	Executive	無	無	無
Erica Osbourne	Executive	無	無	無
Erin Rudsinski	Executive	無	無	無
Loleta Harris	Executive	無	無	無
Neil Thapar	Executive	無	無	無
Nkengyal Barber	Executive	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

公司管治

截至 無 止，ESSA Pharma Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。